Latest News from ASCO in Action

Latest News from ASCO in Action

March 4, 2015

On March 4, 2015, the U. S. Food and Drug Administration granted approval to nivolumab (OPDIVO, Bristol-Myers Squibb Company) for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Nivolumab was previously approved in December, 2014 for the treatment of previously treated unresectable or metastatic melanoma. Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, thereby releasing PD-1 pathway-mediated inhibition of the immune response, including anti-tumor immune response.

March 3, 2015

The American Society of Clinical Oncology (ASCO), the Hematology/Oncology Pharmacy Association (HOPA), and the Oncology Nursing Society (ONS) issued a joint position statement on improving the safety of healthcare workers who handle dangerous drugs and other hazardous materials across various healthcare settings.

March 3, 2015

ASCO, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) will cosponsor a public workshop, “Complexities in Personalized Medicine: Harmonizing Companion Diagnostics across a Class of Targeted Therapies” on March 24, 2015, at the Mayflower Renaissance Hotel in Washington, DC.

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.